FULC - Fulcrum Therapeutics, Inc.
IEX Last Trade
4.7
0.020 0.426%
Share volume: 4,532
Last Updated: Thu 26 Dec 2024 04:30:24 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$4.68
0.02
0.43%
Fundamental analysis
42%
Profitability
25%
Dept financing
3%
Liquidity
75%
Performance
60%
Performance
5 Days
4.60%
1 Month
32.27%
3 Months
31.12%
6 Months
-23.91%
1 Year
-27.55%
2 Year
-27.20%
Key data
Stock price
$4.70
DAY RANGE
$4.50 - $4.70
52 WEEK RANGE
$3.03 - $13.70
52 WEEK CHANGE
-$32.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Bryan E. Stuart
Region: US
Website: fulcrumtx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: fulcrumtx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Fulcrum Therapeutics, Inc. focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin.
Recent news